The huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period

Wednesday, July 24, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 24, 2019 /PRNewswire/ --

Global Age-Related Macular Degeneration (AMD) Therapeutics Market: About this market Read the full report: https://www.reportlinker.com/p05796179/?utm_source=PRN Age-related macular degeneration (AMD) is a bilateral ocular disease that affects the central area of the retina known as the macula. This age-related macular degeneration

considers sales from both wet AMD, dry AMD. Our analysis also considers the sales of AMD in Asia, Europe, North America and ROW. In 2018, the wet AMD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing use of VEGF inhibitors, which are used for the treatment of wet AMD will play a significant role in the wet AMD segment to maintain its market position. Also, our global age-related macular degeneration market report also looks at factors such as high prevalence of AMD, strong pipeline and expected approvals, and rising geriatric populations. However, lack of approved therapies for dry AMD, introduction of biosimilars, side effects of available therapeutics may hamper the growth of the age-related macular degeneration industry over the forecast period.Global Age-Related Macular Degeneration (AMD) Therapeutics Market: OverviewHigh prevalence of AMDThe prevalence of AMD is extremely high, owing to the presence of high-risk factors for developing the condition. Risk factors such as aging, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence coupled with the huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period.Development of gene therapy for AMDThere is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.Competitive LandscapeWith the presence of few major players, the global age-related macular degeneration (AMD) therapeutics market is moderately concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading age-related macular degeneration manufacturers, that include Amgen Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.Also, the age-related macular degeneration market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.Read the full report: https://www.reportlinker.com/p05796179/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-huge-unmet-medical-need-of-dry-amd-is-expected-to-drive-the-market-at-a-cagr-of-over-8-during-the-forecast-period-300890205.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store